Tumor-associated ECs from LLC-allografted, Cds2 vMO-treated mice show markedly reduced levels of PIP2, p-AKT, and p-ERK1/2 (Fig. 4e–g, i; Supplementary Fig. 14G–L). The gene discussed is MAPK3; the disease is neoplasm.